Krka DD (LTS:0HLK) Debt-to-Revenue : 0.01 (As of Mar. 2026)


LTS:0HLK Krka DD LTS:0HLK
84 GF Score
Price €64.80
GF Value €42.03
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krka DD Debt-to-Revenue?

Krka DD LTS:0HLK 84 Debt-to-Revenue is 0.01 as of Mar. 2026. GuruFocus rates LTS:0HLK with a GF Score™ of 84/100 and a GF Value™ of €42.03 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

Krka DD's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €4 Mil. Krka DD's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €14 Mil. Krka DD's annualized Revenue for the quarter that ended in Mar. 2026 was €2,263 Mil. Krka DD's annualized Debt-to-Revenue for the quarter that ended in Mar. 2026 was 0.01.

Krka DD Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Krka DD's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krka DD Debt-to-Revenue Chart

Krka DD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.01 0.01 0.01 0.01

Krka DD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

LTS:0HLK vs ZTS, UTHR, VTRS: Debt-to-Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krka DD Debt-to-Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Krka DD's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Krka DD's Debt-to-Revenue falls into.


LTS:0HLK
84GF Score
Krka DD LTS:0HLK
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krka DD Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Krka DD's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.35 + 14.011) / 2041.025
=0.01

Krka DD's annualized Debt-to-Revenue for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.477 + 13.726) / 2263.096
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2026) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.01 mean?
Krka DD (LTS:0HLK) has a Debt-to-Revenue of 0.01 as of Mar. 2026.
Is Krka DD's Debt-to-Revenue too high?
Krka DD's current Debt-to-Revenue is 0.01. Overall, Krka DD has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Debt-to-Revenue compare to ZTS and UTHR?
Krka DD's Debt-to-Revenue of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Drug Manufacturers company?
A good Debt-to-Revenue depends on the Drug Manufacturers industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Krka DD's current Debt-to-Revenue is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Significantly Overvalued. The stock's GF Value™ is €42.03, compared to a current price of €64.80 — trading 54.2% above its estimated fair value. The current Debt-to-Revenue is 0.01. Krka DD's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current Debt-to-Revenue is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krka DD (LTS:0HLK) Overvalued in 2026?

Based on GuruFocus' analysis, Krka DD stock appears to be overvalued. The current stock price of €64.80 is trading 54.2% above its estimated GF Value™ of €42.03. GuruFocus considers Krka DD to be Significantly Overvalued.

Key valuation signals for LTS:0HLK:

  • Debt-to-Revenue: 0.01
  • GF Value™: €42.03 vs. price of €64.80 (54.2% above fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krka DD Business Description

Address Smarjeska Cesta 6, Novo Mesto, SVN, 8501
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
84GF Score

Get the complete analysis for LTS:0HLK

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.80
Price
€42.03
GF Value